Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Jan 06, 2017, 07:55 ET CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor

Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated...


Jan 06, 2017, 07:00 ET DS Biopharma (DS) Announces that Recruitment has Begun in Two Separate Phase 2b Atopic Dermatitis Studies with Lead Compound DS107 as well as the Successful Completion of a Phase 1 Trial for Follow on Compound DS109

DS Biopharma (DS), a privately held, clinical stage, pharmaceutical drug discovery and development company, today announced that recruitment has...


Jan 06, 2017, 00:13 ET Sun Pharma gibt positive Topline-Ergebnisse der konfirmatorischen klinischen Phase-3-Studie für Seciera™ zur Behandlung des Trockenen Auges bekannt

- Seciera™ erreicht ersten und wichtigen zweiten Endpunkt in Schlüsselstudie - Zeigt Wirksamkeit bei 12 Behandlungswochen - Sun Pharma...


Jan 05, 2017, 20:31 ET Roche gains FDA Clearance for 18-Minute Anti-Müllerian Hormone Test to Assess Ovarian Reserve

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it received clearance from U.S. Food and Drug Administration (FDA) via Direct de novo...


Jan 05, 2017, 16:01 ET Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs

Mirati Therapeutics, Inc. (Mirati or the Company) (NASDAQ: MRTX) today announced data from two ongoing clinical programs, including the Phase 1b...


Jan 05, 2017, 16:01 ET Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™...


Jan 05, 2017, 14:02 ET Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies...


Jan 05, 2017, 11:00 ET Renova Therapeutics selects Worldwide Clinical Trials as its Clinical Research Organization for Phase 3 trial of RT-100 AC6 gene transfer

Renova™ Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced today...


Jan 05, 2017, 09:30 ET Keystone Nano Announces FDA Approval Of Investigational New Drug Application For Ceramide NanoLiposome For The Improved Treatment Of Cancer

Keystone Nano, Inc., a biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today...


Jan 05, 2017, 09:00 ET Iterum Announces Sulopenem in Development for Treatment of Gram-Negative, Multi-drug Resistant Infections

Iterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for...


Jan 05, 2017, 08:30 ET XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing...


Jan 05, 2017, 08:30 ET Juniper Pharmaceuticals Announces Poster Presentation at Society for Maternal-Fetal Medicine 2017 Annual Meeting

Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that an abstract...


Jan 05, 2017, 08:30 ET M2Gen® Announces that Merck Joins the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

M2Gen®, a leading health informatics solutions company, announced today that Merck, known as MSD outside the United States and Canada, has joined...


Jan 05, 2017, 08:00 ET PaxVax Partners with National Institutes of Health and Department of Defense to Develop a New Virus-Like Particle Vaccine to Fight the Spread of Chikungunya

PaxVax announced today its partnership with the National Institutes of Health (NIH) and United States Department of Defense (DoD) on its...


Jan 05, 2017, 08:00 ET PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA...


Jan 05, 2017, 08:00 ET Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-Resistant Depression

Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has...


Jan 05, 2017, 07:00 ET Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its...


Jan 05, 2017, 06:59 ET Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)

Janssen Biotech, Inc. today announced that the company has entered a clinical trial collaboration with Bristol-Myers Squibb Company (BMS) to...


Jan 05, 2017, 06:58 ET Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)

Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and...


Jan 05, 2017, 06:00 ET Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases...


Jan 05, 2017, 03:00 ET Enterome Starts Phase I Clinical Trial With its Lead Candidate EB8018 to Treat Crohn's Disease

EB8018 is a first-in-class oral small molecule targeting the host-microbiome interaction by blocking FimH ENTEROME SA, a pioneer in the...


Jan 05, 2017, 01:30 ET CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food...


Jan 05, 2017, 00:37 ET Sun Pharma annonce des résultats initiaux positifs pour l'essai clinique de confirmation de phase 3 de Seciera™ pour le traitement de la sécheresse oculaire

- Seciera™ satisfait les critères d'évaluation primaires et les principaux critères d'évaluation secondaires lors de l'essai pivot - Se révèle...


Jan 04, 2017, 22:44 ET Sun Pharma anuncia resultados positivos de línea superior del ensayo clínico de fase 3 confirmatorio para Seciera™ para tratar el ojo seco

- Seciera™ cumple las conclusiones primarias y secundarias en un ensayo pivotal - Muestra eficacia a las 12 semanas de tratamiento - Sun...


Jan 04, 2017, 18:45 ET Sun Pharma anuncia resultados positivos de primeira linha para o teste clínico fase 3 confirmatório da Seciera™, para tratamento do olho seco

A Sun Pharma anunciou os bem-sucedidos resultados do teste clínico fase 3 confirmatório para Seciera™ (solução oftalmológica de ciclosporina A,...